OBJECTIVE: Glioblastoma (GBM) remains fatal due to the blood-brain barrier (BBB), which interferes with the delivery of chemotherapeutic agents. The purpose of this study was to evaluate the safety and feasibility of repeated disruption of the BBB (BBBD) with MR-guided focused ultrasound (MRgFUS) in patients with GBM during standard adjuvant temozolomide (TMZ) chemotherapy. METHODS: This study was a prospective, single-center, single-arm study. BBBD with MRgFUS was performed adjacent to the tumor resection margin on the 1st or 2nd day of the adjuvant TMZ chemotherapy at the same targets for 6 cycles. T2*-weighted/gradient echo (GRE) MRI was performed immediately after every sonication trial, and comprehensive MRI was performed at the completion of all sonication sessions. Radiological, laboratory, and clinical evaluations were performed 2 days before each planned BBBD. RESULTS: From September 2018, 6 patients underwent 145 BBBD trials at various locations in the brain. The authors observed gadolinium-enhancing spots at the site of BBBD on T1-weighted MRI in 131 trials (90.3%) and 93 trials (64.1%) showed similar spots on T2*-weighted/GRE MRI. When the 2 sequences were combined, BBBD was observed in 134 targets (92.4%). The spots disappeared on follow-up MRI. There were no imaging changes related to BBBD and no clinical adverse effects during the 6 cycles. CONCLUSIONS: This study is the first in which repetitive MRgFUS was performed at the same targets with a standard chemotherapy protocol for malignant brain tumor. BBBD with MRgFUS was performed accurately, repeatedly, and safely. Although a longer follow-up period is needed, this study allows for the possibility of other therapeutic agents that previously could not be used due to the BBB.Clinical trial registration no.: NCT03712293 (clinicaltrials.gov).
OBJECTIVE:Glioblastoma (GBM) remains fatal due to the blood-brain barrier (BBB), which interferes with the delivery of chemotherapeutic agents. The purpose of this study was to evaluate the safety and feasibility of repeated disruption of the BBB (BBBD) with MR-guided focused ultrasound (MRgFUS) in patients with GBM during standard adjuvant temozolomide (TMZ) chemotherapy. METHODS: This study was a prospective, single-center, single-arm study. BBBD with MRgFUS was performed adjacent to the tumor resection margin on the 1st or 2nd day of the adjuvant TMZ chemotherapy at the same targets for 6 cycles. T2*-weighted/gradient echo (GRE) MRI was performed immediately after every sonication trial, and comprehensive MRI was performed at the completion of all sonication sessions. Radiological, laboratory, and clinical evaluations were performed 2 days before each planned BBBD. RESULTS: From September 2018, 6 patients underwent 145 BBBD trials at various locations in the brain. The authors observed gadolinium-enhancing spots at the site of BBBD on T1-weighted MRI in 131 trials (90.3%) and 93 trials (64.1%) showed similar spots on T2*-weighted/GRE MRI. When the 2 sequences were combined, BBBD was observed in 134 targets (92.4%). The spots disappeared on follow-up MRI. There were no imaging changes related to BBBD and no clinical adverse effects during the 6 cycles. CONCLUSIONS: This study is the first in which repetitive MRgFUS was performed at the same targets with a standard chemotherapy protocol for malignant brain tumor. BBBD with MRgFUS was performed accurately, repeatedly, and safely. Although a longer follow-up period is needed, this study allows for the possibility of other therapeutic agents that previously could not be used due to the BBB.Clinical trial registration no.: NCT03712293 (clinicaltrials.gov).
Entities:
Keywords:
AU = arbitrary unit; BBB = blood-brain barrier; BBBD = disruption of the BBB; GBM = glioblastoma; GRE = gradient echo; MB = microbubble; MRgFUS = MR-guided focused ultrasound; P-gp = P-glycoprotein 1; TMZ = temozolomide; blood-brain barrier; focused ultrasound; glioblastoma; magnetic resonance imaging; oncology; surgical technique
Authors: Scott R Burks; Cymon N Kersch; Jaclyn A Witko; Michael A Pagel; Maggie Sundby; Leslie L Muldoon; Edward A Neuwelt; Joseph A Frank Journal: Proc Natl Acad Sci U S A Date: 2021-05-04 Impact factor: 11.205
Authors: T A Arsiwala; S A Sprowls; K E Blethen; C E Adkins; P A Saralkar; R A Fladeland; W Pentz; A Gabriele; B Kielkowski; R I Mehta; P Wang; J S Carpenter; M Ranjan; U Najib; A R Rezai; P R Lockman Journal: Neoplasia Date: 2021-06-14 Impact factor: 6.218
Authors: Jia Li; Meng Zheng; Olga Shimoni; William A Banks; Ashley I Bush; Jennifer R Gamble; Bingyang Shi Journal: Adv Sci (Weinh) Date: 2021-06-03 Impact factor: 16.806
Authors: Aria Sabbagh; Kevin Beccaria; Xiaoyang Ling; Anantha Marisetty; Martina Ott; Hillary Caruso; Emily Barton; Ling-Yuan Kong; Dexing Fang; Khatri Latha; Daniel Yang Zhang; Jun Wei; John DeGroot; Michael A Curran; Ganesh Rao; Jian Hu; Carole Desseaux; Guillaume Bouchoux; Michael Canney; Alexandre Carpentier; Amy B Heimberger Journal: Clin Cancer Res Date: 2021-05-24 Impact factor: 13.801